Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

Returns on capital

Verrica Pharmaceuticals Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-72.3%

avg 12.7%

ROIC

-38.0%

avg -211.2%

ROA

-37.9%

avg -88.6%

Analysis

ROA is currently the strongest return metric at -37.9% versus its period average of -88.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Chris Chapman

Chief Commercial OfficerUSD 635.38K———

John J. Kirby

Interim Chief Financial OfficerUSD 532.5K5423.96K0.22%

Jayson Rieger

President, Chief Executive Officer & DirectorUSD 391.17K50207.59K1.95%

Noah L. Rosenberg

Chief Medical OfficerUSD 243.32K598.59K0.08%

Bradley J. Catalone

Head of Drug Development————

David Zawitz

COO, Chief Legal Officer & Secretary—4527.00K0.25%

Eugene Scavola

Executive Vice President of Technical Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

18

$24.87M

Sells

0

$0.00

Net Transaction Value

+$24.87M

Net buying

Most Active

Rosenberg Noah L.

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 18, 26

Rosenberg Noah L.

Direct

Buy$10K
Aug 18, 26

Kirby John J.

Direct

Buy$24.7K
Aug 17, 26

Zawitz David

Direct

Buy$29.9K
Aug 17, 26

Rosenberg Noah L.

Direct

Buy$20.6K
Aug 17, 26

Rieger Jayson

Direct

Buy$24.6K
Aug 14, 26

Rieger Jayson

Direct

Buy$101.2K
Nov 25, 25

Rosenberg Noah L.

Direct

Buy$10K
Nov 25, 25

Rosenberg Noah L.

Direct

Buy$3.7K
Nov 25, 25

Kirby John J.

Direct

Buy$15K
Nov 25, 25

Kirby John J.

Direct

Buy$5.6K

1–10 of 18

Summary

Insiders reported 18 buys worth $24.87M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $24.87M. Rosenberg Noah L. was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+57.9%
+14.5% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +57.9% over three years. Forward estimates point to Revenue at +14.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Verrica Pharmaceuticals Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about VRCA's management, answered from reported figures.

Who manages VRCA?

Verrica Pharmaceuticals Inc. (VRCA) lists 7 active executives. The top listed executive is Bradley J. Catalone, Head of Drug Development.

Are VRCA insiders buying or selling?

Recent insider activity shows net buying of $147.14M.